LRIG1 Modulates Cancer Cell Sensitivity to Smac Mimetics by Regulating TNFα Expression and Receptor Tyrosine Kinase Signaling

Longchuan Bai1, Donna McEachern1, Chao-Yie Yang1, Jianfeng Lu1, Haiying Sun1, and Shaomeng Wang1,2,3

Abstract

Smac mimetics block inhibitor of apoptosis proteins to trigger TNFα-dependent apoptosis in cancer cells. However, only a small subset of cancer cells seem to be sensitive to Smac mimetics and even sensitive cells can develop resistance. Herein, we elucidated mechanisms underlying the intrinsic and acquired resistance of cancer cells to Smac mimetics. In vitro and in vivo investigations revealed that the expression of the cell surface protein LRIG1, a negative regulator of receptor tyrosine kinases (RTK), is downregulated in resistant derivatives of breast cancer cells sensitive to Smac mimetics. RNA interference–mediated downregulation of LRIG1 markedly attenuated the growth inhibitory activity of the Smac mimetic SM-164 in drug-sensitive breast and ovarian cancer cells. Furthermore, LRIG1 downregulation attenuated TNFα gene expression induced by Smac mimetics and increased the activity of multiple RTKs, including c-Met and Ron. The multitargeted tyrosine kinase inhibitors Crizotinib and GSK1363089 greatly enhanced the anticancer activity of SM-164 in all resistant cell derivatives, with the combination of SM-164 and GSK1363089 also completely inhibiting the outgrowth of resistant tumors in vivo. Together, our findings show that both upregulation of RTK signaling and attenuated TNFα expression caused by LRIG1 downregulation confers resistance to Smac mimetics, with implications for a rational combination strategy. Cancer Res; 72(5): 1–10. ©2012 AACR.

Introduction

Dysfunction of apoptosis is a hallmark of human cancer and confers resistance to chemo- and radiotherapy. Targeting key apoptosis regulators such as inhibitors of apoptosis (IAP) with the goal of overcoming apoptosis resistance of cancer cells is an attractive therapeutic strategy. The mammalian family of IAPs includes cellular IAP1 (cIAP1, BIRC2), cIAP2 (BIRC3), X-linked IAP (XIAP, BIRC4), survivin (BIRC5), and melanoma IAP (ML-IAP, BIRC7), which are frequently overexpressed in cancer cells and associated with chemoresistance, disease progression, and poor prognosis (1–3). IAPs such as XIAP and cIAP1/2 are endogenously antagonized by Smac/DIABLO (second mitochondria-derived activator of caspases/direct IAP binding with low pl) through interaction of the N-terminal AVPI tetrapeptide of Smac with the baculovirus IAP repeat domains of IAPs (4, 5). Small molecules that have been designed to mimic the IAP-binding AVPI motif of Smac (known as Smac mimetics) function as antagonists of multiple IAPs. Smac mimetics can potently induce apoptosis in some cancer cell lines and inhibit tumor growth in xenograft tumor models (6–11). Five such compounds are currently in early clinical development as a novel class of anticancer drugs (1, 2).

Smac mimetics target cIAP1/2 and XIAP to induce TNFα-dependent apoptosis (8–10). However, only a small subset of cancer cell lines is prone to Smac mimetic–induced apoptosis (8, 12). Exogenous TNFα, TRAIL (6, 8, 12), and IL-1β (13) all significantly enhance the ability of Smac mimetics to induce apoptosis. Downregulation of c-FLIP also enhances Smac mimetic–induced apoptosis in a variety of human cancer cell lines (12). Preclinical studies showed that xenograft tumors initially responding to Smac mimetic treatment regrow after treatment ends, indicating emergence of Smac mimetic–tolerant cells in the tumors (8). In lung cancer cells, cIAP2 protein levels rebound following Smac mimetic treatment, and inhibition of cIAP2 expression sensitizes resistant cells to Smac mimetic treatment in vitro, suggesting one mechanism for tumor cells to evade Smac mimetic–induced apoptosis (14).

Hence, the clinical benefit of Smac mimetic–based cancer therapy will be limited by intrinsic and/or acquired drug resistance. An in-depth understanding of the resistant mechanisms to Smac mimetics will help to identify the patients most likely to respond to this new class of drugs and to develop mechanistic based approaches to overcome drug resistance. In
this study, we investigated the mechanisms of resistance to Smac mimetics in breast and ovarian cancer cells using a highly potent Smac mimetic SM-164, which contains 2 nonpeptidic mimetics of the AVPI tetrapeptide binding motifs and mimics the natural dimeric Smac protein (7, 15).

Materials and Methods
Reagents and antibodies
Bivalent SM-164 and monovalent SM-406/AT-406 were described previously (7, 16). PF2341066 (Crizotinib), GSK1363089 (XL-880), AT-7867, U0126, and SKI-606 were purchased from Selleck Chemicals. A detailed list of reagents and antibodies used are in Supplementary Information Materials and Methods.

Cell culture, cell viability and apoptosis assays
MDA-MB-231, SKOV-3, MDA-MB-453, HCC38, HCC70, and OVCAR-4 cell lines were purchased from American Type Culture Collection (ATCC) and cultured as recommended. All these cell lines were authenticated by ATCC and were passaged fewer than 6 months after purchase for all the experiments. Cell viability was measured by a WST-8 assay (Dojindo; ref. 7). Apoptosis was analyzed using an Annexin V/propidium iodide (PI) detection kit (Roche). In combination studies, drugs were added simultaneously to the cells and combination index (CI) was calculated using the Chou-Talalay method (17).

Microarray analysis and quantitative RT-PCR
Total RNA was isolated with an RNA MiniPrep kit (Sigma). Affymetrix human U133 Plus 2.0 chips were used for the hybridization. For real-time PCR, cDNA was synthesized using cDNA reverse transcription kits (Applied Biosystems). TaqMan gene expression assays were carried out sized using cDNA reverse transcription kits (Applied Biosystems). Affymetrix human U133 Plus 2.0 chips were used for the hybridization. For real-time PCR, cDNA was synthesized using cDNA reverse transcription kits (Applied Biosystems). Real-time PCR was carried out following protocol described (7). Concentrations of secreted TNFα in culture medium were detected using the Quantikine HS Human TNFα ELISA kit (R&D Systems; ref. 7).

RNA interference, immunoblotting, and TNFα ELISA
ON-TARGETplus SMARTpools for LRIG1, TNFR1, Ron, c-Met, and nontargeting negative control siRNAs were from Dharmacon. Transfection was done using Lipofectamine RNAiMAX (Invitrogen). Immunoblotting was carried out as described (7). Concentrations of secreted TNFα in culture medium were measured using the QuantiKine HS Human TNFα ELISA kit (R&D Systems; ref. 7).

In vivo xenograft studies
In vivo studies were conducted under a protocol approved by the University Committee on Use and Care of Animals of the University of Michigan. Severe combined immunodeficient (SCID) mice bearing xenograft tumors were treated with SM-164 as described before (7). Tumor sizes were measured 2 to 3 times per week.

Statistical analyses
For the cell viability assay, data were plotted as mean ± SD and sigmoid fitted (variable slope). Differences in means of cell viability among different groups were analyzed by 2-way ANOVA. For in vivo studies, significance (P) was calculated by Student t test, with a P value of less than 0.05 being considered as significant. All statistical tests were 2-sided, and all statistical analyses were carried out using GraphPad Prism 5.

Results
Lack of TNFα production contributes to Smac mimetic resistance in the sublines from MDA-MB-231 xenograft tumors
As a potent Smac mimic, SM-164 displays a strong in vitro anticancer activity against a subset of human cancer cell lines (7). It also effectively inhibits tumor growth in the xenograft model of the MDA-MB-231 human breast cancer cell line (7). Although SM-164 achieved partial tumor regression, all the regressed tumors started to regrow after treatment ended (Fig. 1A), similar to a previous observation that HCC461 non–small cell lung xenograft tumors treated with another potent Smac mimic (8). These data indicated that resistant cancer cells emerge from initially sensitive tumors following Smac mimetic treatment.

To elucidate the resistant mechanisms, we isolated MDA-MB-231 tumor cells from the regrown tumors and established 8 sublines. These 8 sublines exhibited polarized sensitivity to SM-164 treatment, with T2, T3, T4, and T5 sublines resistant (IC50 > 200 nmol/L) and T1, T6, T7, and T8 sublines sensitive (IC50 < 20 nmol/L) to SM-164 (Fig. 1B). Extended treatment of resistant sublines only modestly increased their susceptibility to SM-164 (Supplementary Fig. S1A), suggesting that the resistance is not due to a delayed response to SM-164. The 4 SM-164–resistant sublines were also cross-resistant (IC50 > 5 μmol/L) to a monovalent Smac mimetic AT-406 (ref. 16; Supplementary Fig. S1B). Consistently, SM-164 effectively induced cleavage of caspase-3 and PARP, 2 biochemical markers for apoptosis, in parental and the sensitive sublines but not in the resistant sublines (Fig. 1C).

SM-164, like other Smac mimetics, targets cIAP1/2 and induces TNFα-dependent apoptosis following cIAP1/2 degradation and NF-κB activation (7). However, there was no significant difference in SM-164–induced degradation of cIAP1/2 and key molecular events in canonical and noncanonical NF-κB activation [upregulation of NF-κB–inducing kinase (NIK), phosphorylation of p65(Ser536), and processing of p100] among the parental cells, sensitive and resistant sublines (Fig. 1C, Supplementary Fig. S2A). Interestingly, although SM-164 induced robust production of TNFα in the parental cells and sensitive sublines in culture medium, it only weakly increased the levels of TNFα protein in all the resistant sublines (Fig. 1D, Supplementary Fig. S2B). Real-time reverse transcription PCR (RT-PCR) revealed that although TNFα mRNA levels were reduced in all the MDA-MB-231 tumor
sublines compared with the parental cells, there was no significant difference between the sensitive and resistant sublines (Supplementary Fig. S2C). However, SM-164 significantly enhanced TNFα mRNA expression in the parental cell line and all the sensitive sublines, but not in the resistant sublines (Supplementary Fig. S2D). Of note, all the resistant sublines still respond to TNFα-induced autocrine upregulation (Supplementary Fig. S2D), suggesting that SM-164 and TNFα induce TNFα mRNA expression via distinct mechanisms.

To determine whether lack of SM-164–induced TNFα production is responsible for the resistance, we treated cells with SM-164 together with recombinant human TNFα. Although exogenous TNFα only modestly enhanced the activity of SM-164 in the parental cells and T6-sensitive subline, it dramatically potentiated SM-164–induced apoptosis in all the resistant sublines (Fig. 1E), indicating that the TNFα-mediated apoptotic pathway was intact in these resistant cells. Indeed, the parental cells as well as the T2-resistant and T6-sensitive sublines expressed comparable levels of TNFR1, RIPK1, FADD, TRADD, and TRAF2, key components for TNFα-mediated signaling (Supplementary Fig. S2A). Although the expression of cIAP2 was enhanced by exogenous TNFα, SM-164 still efficiently reduced cIAP2 levels in these cells (Supplementary Fig. S2A). Recombinant TNFα or TRAIL both also restored the sensitivity of all the resistant sublines to SM-164 (Supplementary Fig. S2E). However, conditioned medium from MDA-MB-231 cells treated with SM-164 only modestly enhanced the activity of SM-164 in these resistant sublines (Supplementary Fig. S2E), suggesting that these resistant cells have a higher threshold for TNFα-mediated apoptosis upon Smac mimetic treatment and there must be additional factor(s) contributing to the resistance in these cells.

Figure 1. Characterization of tumor cells isolated from MDA-MB-231 xenograft tumors treated with SM-164. A, MDA-MB-231 xenograft tumors were treated with 5 mg/kg of SM-164 intravenously 5 days per week for 2 weeks. B, tumor cells (T1–8) isolated from the MDA-MB-231 xenografts were treated with SM-164 for 2 days and cell viability was evaluated by WST assay. Data are representative from 3 independent experiments. C, cells were treated with 5 nmol/L of SM-164 for 16 hours for immunoblotting. D, cells were treated with 5 nmol/L of SM-164 for 5 hours for ELISA. Data (mean ± SD) are from triplicate, including both early (Annexin V-positive/PI-negative) and late (Annexin V–positive/PI-positive) apoptotic cells. F, immunoblotting for LRIG1 and GAPDH. P, MDA-MB-231 parental cells.
LRIG1 is downregulated in the in vivo–selected MDA-MB-231 resistant sublines

To further dissect the resistant mechanisms, we employed genome-wide gene expression profiling to identify genes that may be associated with the resistance using T2- and T3-resistant sublines, T6- and T8-sensitive sublines, and the parental cells. Surprisingly, only 10 genes were consistently differentially expressed by more than 1.5-fold in T2- and T3-resistant sublines compared with T6- and T8-sensitive sublines and the parental cells in Affymetrix microarray analysis (Supplementary Table S1). Real-time RT-PCR and immunoblotting analyses of 9 genes with known functions in all 4 resistant sublines, 4 sensitive sublines, and the parental cells showed that only LRIG1 (leucine-rich repeats and immunoglobulin-like domains 1) and WT1 (Wilms Tumor 1) are consistently differentially expressed between the resistant and sensitive groups of cells (Fig. IF, Supplementary Fig. S3A and B).

Functional validation showed that knockdown of LRIG1, but not WT1 and 4 other genes, by siRNAs significantly attenuated the growth inhibitory activity of SM-164 in MDA-MB-231 cells (Supplementary Fig. S3C and D). LRIG1 is a putative tumor suppressor whose ectopic expression inhibits the growth of a variety of cancer cell lines in vitro and negatively regulates multiple receptor tyrosine kinases (RTK) by enhancing their ubiquitination and degradation (18–27). LRIG1 also regulates epidermal stem cell quiescence, and its expression defines a distinct multipotent stem cell population in mammalian epidermis (28, 29).

Downregulation of LRIG1 confers resistance to SM-164

We further characterized the role of LRIG1 in the regulation of Smac mimetic activity. Knockdown of LRIG1 as well as TNFRI markedly attenuated the growth inhibitory activity of SM-164 in MDA-MB-231 and SKOV-3 ovarian cancer cells (Fig. 2A). However, knockdown of epidermal growth factor receptor (EGFR), a known target of LRIG1 (18, 23, 27), had no significant effect on the activity of SM-164 (Fig. 2A). Silencing LRIG1 greatly reduced apoptosis induction by SM-164 in both cell lines (Supplementary Fig. S4A) and also significantly attenuated SM-164–induced cleavage of PARP, but had no significant effect on SM-164–induced degradation of cIAP1 and cIAP2 (Fig. 2B). Neither the protein levels nor surface expression of TNFR1 were significantly altered by the depletion of LRIG1 (Fig. 2B, Supplementary Fig. S4B). The possible off-target effects of the siRNA against LRIG1 were excluded by employing multiple siRNAs targeting different regions of LRIG1 mRNA (Supplementary Fig. S4C, S4D). The growth inhibitory activity of SM-164 was also reduced upon silencing LRIG1 in 4 additional SM-164–sensitive breast and ovarian cancer cell lines (Supplementary Fig. S5), suggesting that LRIG1 may be a common regulator of the activity of Smac mimetics.

LRIG1 expression is downregulated in SM-164–resistant cells derived from MDA-MB-231 and SKOV-3 cells treated with SM-164 in vitro

To determine whether the resistance observed in the SM-164–treated MDA-MB-231 tumors in mice can be recaptured by treating the parental cells in vitro, we obtained SM-164–tolerant cells (MDA-MB-231/R) by treating MDA-MB-231 cells with SM-164 at 50 nmol/L, 10 times of its IC50 value, for more than 3 weeks. The MDA-MB-231/R cells became highly resistant to SM-164 (Fig. 3A) and also failed to produce TNFα upon SM-164 treatment (Fig. 3B). Real-time RT-PCR showed that both LRIG1 and TNFα expression were reduced in MDA-MB-231/R cells compared with the parental cells (Fig. 3C and D). Similarly, SM-164–resistant SKOV-3 cells (SKOV-3/R) were obtained by treatment of SKOV-3 cells with SM-164 at concentrations 10 times of its IC50 for more than 3 weeks (Supplementary Fig. S6A). Compared with the parental cells, the SKOV-3/R cells had reduced levels of LRIG1 protein, and SM-164–induced TNFα production and apoptosis were much reduced in the resistant cells (Supplementary Fig. S6B and C).

To investigate whether the resistance to SM-164 obtained from in vitro and in vivo is acquired during treatment or results from a selection of preexisting resistant subpopulations, we isolated and evaluated single clones of MDA-MB-231 cells. Of 106 clones evaluated, 3 (2F4, 3E8, and 3F7) were highly resistant to SM-164 (Fig. 3A). The remaining 103 clones were equally sensitive to SM-164 as the parental cell line. The 3 resistant clones had greatly reduced mRNA expression for both LRIG1 and TNFα (Fig. 3C and D) and failed to produce TNFα upon treatment with SM-164 (Fig. 3B).
Collectively, these data suggested that Smac mimetic resistant cells preexist in the bulk population of parental cells, and SM-164 treatment selectively enriches the resistant subpopulations, which share a common attribute of reduced expression of LRIG1 and are unable to produce TNFα upon treatment with SM-164.

LRIG1 regulates SM-164 induced TNFα expression

We next investigated whether there is a potential direct link between LRIG1 and SM-164–induced TNFα production. Upon knockdown of LRIG1, SM-164–induced TNFα production was significantly attenuated in both MDA-MB-231 and SKOV-3 cell lines (Fig. 4A and B), and SM-164 induced TNFα mRNA expression was also attenuated (Fig. 4C and D). In contrast, TNFα– or lipopolysaccharide (LPS)–induced TNFα mRNA expression was either marginally affected or even enhanced upon knockdown of LRIG1 in these cell lines (Fig. 4C and D). These observations were consistent with our findings that SM-164–, but not TNFα–induced TNFα mRNA expression was diminished in the LRIG1 low expressing resistant cells (Supplementary Fig. S2D). Furthermore, depletion of LRIG1 significantly attenuated SM-164–induced TNFα promoter activity in MDA-MB-231 cells (Supplementary Fig. S7A). Protein synthesis inhibitor cycloheximide (CHX) efficiently blocked SM-164–, but not TNFα– or LPS–induced TNFα mRNA expression (Fig. 4E and F), suggesting that SM-164–induced TNFα mRNA expression requires de novo protein synthesis. Thus, knockdown of LRIG1 in Smac mimetic sensitive cancer cells recapitulates the phenotypic features of in vivo and in vitro selected resistant cells, and LRIG1 modulates the activity of SM-164, at least in part, by directly regulating SM-164–induced TNFα expression.

Because Smac mimetics induce NF-κB–stimulated production of TNFα (9), we assessed the effects of LRIG1 knockdown on the NF-κB components. Depletion of LRIG1 had no significant effect on SM-164–induced phosphorylation of IkBα (S32/36) and p65(S536) (indicators of the activation of the canonical NF-κB pathway), and upregulation of NIK and processing of p100 protein (indicators of the activation of the noncanonical NF-κB pathway) in MDA-MB-231 cells (Supplementary Fig. S7B). Depletion of p65 (Rel A), a subunit of NF-κB complex, indeed diminished the constitutive expression of TNFα in MDA-MB-231 cells (Supplementary Fig. S7C–E). Collectively, these data suggested that, whereas constitutive expression of TNFα requires NF-κB, LRIG1 specifically regulates Smac mimic–induced TNFα expression.

Multiple RTKs are upregulated in MDA-MB-231–resistant cells

LRIG1 negatively regulates several RTKs by enhancing their degradation (18–27). Indeed, the levels of multiple phospho-RTKs were increased in the resistant cells compared with the parental cells, on the basis of phospho-RTKs profiling of the MDA-MB-231 parental and its T2-resistant cells (Supplementary Fig. S8A). The cross-talk between different members of the RTK superfamily is prevalent in cancer cells, and the RTK coactivation is an important mechanism by which cancer cells achieve drug resistance (30). Phospho-tyrosine profiling revealed that the levels of total tyrosine phosphorylation, particularly those proteins between 80 and 200 kDa, were much higher in all the resistant sublines cells than in parental and sensitive sublines (Supplementary Fig. S8B). Immunoblotting showed that, although there was no major difference in the protein levels of IAPs and TNF receptors, the levels of
multiple RTKs were much higher in the resistant sublines than in the sensitive sublines and parental cells (Fig. 5A, Supplementary Fig. S8C1).

RTK signaling activates multiple downstream effector pathways, including Ras-Raf-MEK-ERK and PI3K-Akt-mTOR-p70S6K (31, 32). RTKs also activate Src family kinases to propagate signaling cascade (33). Phosphorylation at certain residues of the signaling nodes indicates the activation status of these pathways. The levels of p-Src(Y416), p-p70S6K(T389), and p-Akt(S473; Fig. 5A, Supplementary Fig. S8C2) were increased in the resistant sublines compared with the sensitive sublines, indicating an enhanced activation of Src and PI3K-Akt pathways in the resistant sublines. No significant difference was observed in the levels of p-ERK1/2(S202/Y204) among the parental, sensitive, and resistant sublines (Supplementary Fig. S8C2). Furthermore, silencing LRIG1 also increased the levels of multiple RTKs, such as c-Met and Ron, in MDA-MB-231 and SKOV-3 (Fig. 5B), indicating a direct role of LRIG1 in regulating these RTKs.

Synergy between tyrosine kinase inhibitors and SM-164 in resistant sublines

Ron and c-Met were frequently, though not uniformly, upregulated in the resistant MDA-MB-231 sublines (Fig. 5A). Knockdown of c-Met and Ron individually had no profound effect on TNFα expression and modestly enhanced the sensitivity of the T2-resistant cells to SM-164 (Supplementary Fig. S9), suggesting that multiple RTKs contribute to Smac mimic resistance and simultaneous blockade of multiple RTK signaling is necessary to sensitize the resistant cells to SM-164. We therefore tested 3 multitargeted tyrosine kinase inhibitors (TKI) on the activity of SM-164 in the resistant cells.

GSK1363089 (GSK) and PF2341066 (PF) are potent inhibitors of c-Met, Ron, and several other RTKs (34–36). SKI-606 (SKI) is a dual-inhibitor of Src and Abi kinases with activity against other tyrosine kinases (37, 38). Although these TKIs alone had a modest growth inhibitory effect (IC50 > 5 μmol/L) against the T2-resistant cells (Supplementary Fig. S10A), they greatly enhanced the activity of SM-164, with a CI (17) ranging from 0.25 to 0.61 (Fig. 5C). U0126, a selective inhibitor of MEK1/2, or AT-7867 (AT), a dual inhibitor of Akt and p70S6 kinase, minimally or modestly enhanced the activity of SM-164, respectively (Fig. 5C). Combination treatment of SM-164 with GSK or SKI led to a significant increase in PARP cleavage and a decrease in cyclin D1 protein compared with single agents (Fig. 5D), suggesting that both induction of apoptosis and inhibition of cell proliferation contribute to the synergy between SM-164 and these TKIs. Interestingly, either GSK or SKI had no major effect on TNFα expression or production (Supplementary Fig. S10B and S10C). Synergy was also observed between SM-164 and GSK, PF or SKI in other MDA-MB-231–resistant sublines (Supplementary Fig. S10D). No
obvious synergy was observed when TNFα or TRAIL was combined with any of these kinase inhibitors against MDA-MB-231 parental or the T2-resistant cells (Supplementary Fig. S11).

Combination of SM-164 with GSK1363089 effectively inhibits the growth of MDA-MB-231–resistant tumors

We next investigated the activity of SM-164 in combination with GSK against resistant tumors in vivo. SCID mice bearing T2 tumors were treated with 5 mg/kg of SM-164 intravenously and/or 10 mg/mL of GSK orally. The levels of p-c-Met (Y1234/1235) were diminished 6 hours after GSK was administered and remained undetectable at 24-hour posttreatment (Fig. 6A). The reduction of p-c-Met (Y1234/1235) was accompanied with a decrease in the levels of p-Src (Y416), p-Akt (S473), and p-ERK (T202/Y204), mediators of RTK downstream effector pathways (Supplementary Figure 5.)

Figure 5. Multiple RTKs are upregulated in MDA-MB-231–resistant sublines, and TKIs enhance the growth inhibitory activity of SM-164. A, protein expression profiling of RTKs in MDA-MB-231 parental and sublines by immunoblotting. B, cells were transfected with negative control or LRIG1-specific siRNAs for 2 days, and cell lysates were immunoblotted to detect the indicated proteins. C, T2 cells were treated with SM-164 and/or the TKIs for 2 days and cell viability was assessed by WST assay. Data are representative of 3 independent experiments. D, T2 cells were treated with 20 nmol/L of SM-164 and/or 1.5 µmol/L of GSK or SKI for 40 hours for immunoblotting.

Figure 6. Antitumor activity of SM-164 and GSK1363089 alone and in combination against T2-resistant tumors. A, SCID mice bearing T2-resistant tumors were treated with 5 mg/kg of SM-164 intravenously and/or 10 mg/mL of GSK orally for the indicated time points. Tumor lysates were immunoblotted to detect the indicated proteins. B, SCID mice bearing T2-resistant tumors were treated with 5 mg/kg of SM-164 intravenously and/or 10 mg/mL of GSK orally for 5 days per week for 2 weeks. Data shown are mean ± SEM for 6 to 8 mice. Asterisks indicate significant difference (P < 0.05).
Fig. S12A). The combination also led to significant decrease of cyclin D1 and increase of PARP cleavage in the tumors (Fig. 6A). We next determined the tumor growth inhibitory activity of the combination. Although SM-164 or GSK alone had a modest antitumor activity, their combination effectively repressed tumor growth (Fig. 6B). Of note, the T2-resistant tumors were very aggressive and one mouse each from the vehicle control and SM-164 groups died of complications of tumor invasion on days 7 and 9, respectively. The doses tested were well tolerated, and body weight was not significantly affected with the treatments (Supplementary Fig. S12B).

Discussion

Five Smac mimetics are being tested in the clinic as new anticancer agents (1, 2). Preclinical studies showed that the majority of cancer cell lines is resistant to Smac mimetics and that the lack of TNFα production upon Smac mimetic treatment is the dominant mechanism of intrinsic resistance to Smac mimetics (2, 7, 8, 12). Even when tumors initially respond to Smac mimetics, they may subsequently acquire resistance. Therefore, understanding resistant mechanisms of tumor cells to Smac mimetics can guide the rational development of Smac mimetics. In this study, using in vitro and in vivo selected resistant models, we identified LRIG1 as a key regulator of resistance of tumor cells to Smac mimetics in breast and ovarian cancer cell lines (Fig. 5A, Supplementary Fig. S8C). RTKs are promising targets for cancer treatment based on their key roles in regulating critical cellular processes; and aberrant RTK activation has been implicated in cancer resistance to molecular-targeted therapies (32). It has been reported that combining a Smac mimic with inhibitors of PDGFR, IGF1R, or EGFR increases cell death compared with monotherapy in human glioblastoma multiforme (39). Synergy between Smac mimetics and inhibitors of FLT3 and BCR-ABL was also observed against leukemia in vitro and in vivo (40, 41). In breast cancer cells, a Smac mimic modestly increased apoptosis induction by ErbB antagonists in Her2- or EGFR-overexpressing cells (42). These data, coupled with our findings suggest that combination of Smac mimetics with TKIs can be a promising approach for the treatment of certain subtypes of cancer.

We found that inhibition of multiple RTKs by TKIs, but not the silencing of individual RTKs, significantly enhances the sensitivity of MDA-MB-231–resistant sublines to SM-164, consistent with our observation that multiple RTKs are upregulated in the SM-164–resistant cells. Importantly, SM-164 in combination with GSK1363089 effectively inhibited the tumor growth of Smac mimetic–resistant cells of MDA-MB-231 (Fig. 6B), suggesting that TKIs can be used to overcome or delay the emergence of Smac mimetic resistance.

Smac mimetics induce activation of both canonical and noncanonical NF-kB pathways, regardless of whether the cells are sensitive or resistant to Smac mimic–mediated growth inhibition (9, 10). However, only Smac mimetics–sensitive cells produce TNFα upon the activation of NF-kB, resulting in apoptosis in an autocrine manner (9, 10). In our studies, there is no significant difference in the molecular events of NF-kB activation between the sensitive and resistant sublines of MDA-MB-231 cells (Supplementary Fig. S2A). In Smac-mimetic–sensitive cells, knockdown of LRIG1 attenuated TNFα mRNA expression induced by Smac mimetics, but not by TNFα or LPS, suggesting that manipulation of LRIG1 expression has minimal effect on classical NF-kB activation. Indeed, knockdown of LRIG1 expression had no significant effect on SM-164–mediated activation of canonical and noncanonical NF-kB pathways in MDA-MB-231 cells (Supplementary Fig. S7B). Instead, our data suggest that Smac mimetics induce TNFα expression through a mechanism different from that of TNFα or LPS and Smac mimetic–enhanced TNFα expression requires de novo protein synthesis (Fig. 4). Additional studies are needed to elucidate the precise mechanism of how LRIG1 regulates the TNFα expression induced by Smac mimetics.

Downregulation of LRIG1 leads to upregulation of multiple RTKs (Fig. 5A). It has been reported that activation of RTKs such as Ron and Axl suppresses TNFα expression in immune cells via downregulation of NF-kB activation and/or upregulation of the transcription factor Twist (43–45). However, we did not observe any significant differences in the expression of either Twist1 or Twist2 between parental cells, resistant and sensitive sublines of MDA-MB-231.

Recently, the rebound of cIAP2 expression upon Smac mimetic treatment of lung cancer cells was described as a mechanism of Smac mimetic resistance (14). In our studies, protein levels of cIAP2 and other key regulators of extrinsic apoptotic pathways are not significantly different between sensitive and resistant sublines (Supplementary Fig. S8C), and cIAP2 was efficiently targeted by SM-164 (Supplementary Fig. S2A), suggesting the existence of more than one resistant mechanism to Smac mimetics. Our findings that both the in vivo and in vitro selected resistant cells from the MDA-MB-231 cell line have a similar attribute of low LRIG1 expression suggesting that, in the bulk population of MDA-MB-231 cells, there is a small population of cells intrinsically resistant to Smac mimetics.

In summary, our study has identified a novel mechanism of Smac mimetics resistance and provided a basis for development of rational combination strategies to overcome such resistance.

Disclosure of Potential Conflicts of Interest

S. Wang is a consultant for and owns stocks and stock options in Ascenta Therapeutics, which has licensed the IAP inhibitors from the University of...
Michigan for clinical development. The other authors disclosed no potential conflicts of interest.

Grant Support
The work received support from Breast Cancer Research Foundation (S. Wang), NIH, National Cancer Institute (NCI) R01CA109025 (S. Wang) and R01CA127553 (S. Wang), and University of Michigan Cancer Center Core grant from the NCI P30CA046592.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 25, 2011; revised November 20, 2011; accepted December 30, 2011; published OnlineFirst January 12, 2012.

References


www.aacrjournals.org


Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC. TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J Leukoc Biol 2010;87:869–75.


LRIG1 Modulates Cancer Cell Sensitivity to Smac Mimetics by Regulating TNF α Expression and Receptor Tyrosine Kinase Signaling

Longchuan Bai, Donna McEachern, Chao-Yie Yang, et al.

Cancer Res  Published OnlineFirst January 12, 2012.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-11-2428

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2012/01/12/0008-5472.CAN-11-2428.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2012/02/11/0008-5472.CAN-11-2428. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.